rhAmpSeq™ CRISPR Panels
Integrated DNA Technologies Inc.Highly multiplexed, targeted amplicon sequencing for critical analysis of your CRISPR edits
Showing 13 products from Integrated DNA Technologies Inc. in Environmental
Highly multiplexed, targeted amplicon sequencing for critical analysis of your CRISPR edits
NGS-ready amplicon libraries. Fast. Easy. Convenient.
LiquidPlex panel is an advanced and user-friendly research assay for targeted next generation sequencing of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly associated with solid tumor type cancers.
FusionPlex Lung v2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 17 genes associated with NSCLC.
FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.
FusionPlex Core Solid Tumor is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 57 genes associated with various solid tumor malignancies.
FusionPlex Pan Solid V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, and fusions, including novel fusions, from 137 genes associated with various solid tumor malignancies.
Immunoverse is a research assay that characterizes the immune repertoire, including assessment of T- and B-cell clonalities and rare clones, and detection of tumor infiltrating lymphocytes (TIL) and somatic hypermutation with targeted NGS of key T cell receptor and B cell receptor chain RNA relevant for blood cancer and solid tumor research.
FusionPlex Pan Heme is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 199 genes associated with lymphoid and myeloid malignancies.
FusionPlex Heme V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 87 genes associated with lymphoid and myeloid malignancies.
FusionPlex Myeloid is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 84 genes associated with myeloid-origin malignancies.
FusionPlex Lymphoma is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 125 genes associated with lymphomas.
FusionPlex ALL is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 81 genes associated with acute lymphoblastic leukemia (ALL) .